Zimbabwe has declined a significant US health deal worth $367m (£272m) spanning five years due to the United States' insistence on sensitive biological samples.
This move was revealed after a government memo from December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "unbalanced".
An official representative has since stated that the US was demanding access to biological samples for scientific study and commercial purposes while was not willing to guarantee the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further dialogue to secure a agreement agreeable to both sides so the country's vital HIV programme can proceed.
Wider Context
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court halted a similar health funding agreement after concerns were raised about the security of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump argued its spending was "wasteful" and his government was pursuing direct bilateral deals to boost openness and responsibility.
According to statements, 16 African countries have to date signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, with no equivalent promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"In essence, our country would provide the basic resources for medical research with no assurance that the final treatments would be accessible to our people if a new health crisis emerge."
National Interest and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting structures already set up through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a country contributes its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome ongoing dialogue with our US partners on how future collaboration might be structured in a way that honours the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the official position, but recommended that negotiations should continue given that much of the country's Aids initiatives were funded by foreign aid.
"If specific concerns exist, such as those involving information security or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," the group commented.
The situation underscores the continuing tensions between receiving crucial international aid and protecting local interests in an increasingly data-driven world.